120 related articles for article (PubMed ID: 16210675)
1. Chemosensitivity and chemoresistance testing.
Markman M
J Clin Oncol; 2005 Oct; 23(29):7363-4. PubMed ID: 16210675
[No Abstract] [Full Text] [Related]
2. Ovarian cancer: strategies for overcoming resistance to chemotherapy.
Agarwal R; Kaye SB
Nat Rev Cancer; 2003 Jul; 3(7):502-16. PubMed ID: 12835670
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Helou K; Horvath G
Cancer Genet Cytogenet; 2005 Dec; 163(2):144-50. PubMed ID: 16337857
[TBL] [Abstract][Full Text] [Related]
4. [Intraperitoneal chemotherapy in ovarian carcinoma. Life prolonging in selected patients].
Ottevanger PB
Ned Tijdschr Geneeskd; 2009 Mar; 153(11):503-7. PubMed ID: 19402326
[No Abstract] [Full Text] [Related]
5. Chemosensitivity and chemoresistance testing in ovarian cancer.
Cree IA
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):39-43. PubMed ID: 19125002
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal chemotherapy for women with epithelial ovarian cancer.
Trimble EL; Thompson S; Christian MC; Minasian L
Oncologist; 2008 Apr; 13(4):403-9. PubMed ID: 18448554
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
[TBL] [Abstract][Full Text] [Related]
8. Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance?
Larsen E; Blaakaer J
Acta Obstet Gynecol Scand; 2009; 88(4):373-7. PubMed ID: 19253061
[TBL] [Abstract][Full Text] [Related]
9. [Chemoresistance/Chemosensitivity of ovarian cancer--a case report].
Sedláková I; Tosner J; Rezác A; Cervinka M; Tomsová M; Spacek J
Ceska Gynekol; 2008 Jun; 73(3):140-3. PubMed ID: 18646664
[TBL] [Abstract][Full Text] [Related]
10. Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer.
Holloway RW
Gynecol Oncol; 2010 Jan; 116(1):147-8; author reply 149-50. PubMed ID: 19767066
[No Abstract] [Full Text] [Related]
11. Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer.
Popadiuk CM; Xiong J; Wells MG; Andrews PG; Dankwa K; Hirasawa K; Lake BB; Kao KR
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2216-23. PubMed ID: 16609037
[TBL] [Abstract][Full Text] [Related]
12. [Chemosensitivity testing in ovarian cancer--prospects for the future].
Pogońska P; Wydra D; Serkies K; Kobierski J; Łojkowska A
Ginekol Pol; 2014 Sep; 85(9):695-8. PubMed ID: 25322542
[TBL] [Abstract][Full Text] [Related]
13. [Time interval between ovarian cancer surgery and chemotherapy--secondary publication?].
Larsen EP; Blaakaer J
Ugeskr Laeger; 2009 Nov; 171(45):3265-8. PubMed ID: 19916194
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitivity assays: still eyeing the clinic.
Jenks S
J Natl Cancer Inst; 2012 Dec; 104(23):1775-7. PubMed ID: 23213182
[No Abstract] [Full Text] [Related]
15. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Staaf J; Sundfeldt K; Horvath G
Cytogenet Genome Res; 2009; 125(1):8-18. PubMed ID: 19617691
[TBL] [Abstract][Full Text] [Related]
16. In vitro drug resistance versus chemosensitivity: two sides of different coins.
Fruehauf JP; Alberts DS
J Clin Oncol; 2005 May; 23(15):3641-3; author reply 3646-8. PubMed ID: 15908686
[No Abstract] [Full Text] [Related]
17. Targeted therapies: tailored treatment for ovarian cancer: are we there yet?
Sessa C; Del Conte G
Nat Rev Clin Oncol; 2010 Feb; 7(2):80-2. PubMed ID: 20118979
[No Abstract] [Full Text] [Related]
18. ACOG Committee Opinion No. 396. Intraperitoneal chemotherapy for ovarian cancer.
American College of Obstetricians and Gynecologists
Obstet Gynecol; 2008 Jan; 111(1):249. PubMed ID: 18165421
[TBL] [Abstract][Full Text] [Related]
19. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer.
Markman M
Cancer J; 2009; 15(2):105-9. PubMed ID: 19390303
[TBL] [Abstract][Full Text] [Related]
20. [Actual state of ex vivo chemoresistance testing of malignant tumors in Masaryk Memorial Cancer Institute Brno].
Poprach A; Michalová E; Pavlík T; Lakomy R; Vyskocil J; Nemeccek R; Zaloudík J; Vyzula R; Kocák I; Kocáková I
Klin Onkol; 2008; 21(3):116-21. PubMed ID: 19097421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
